^
    13d
    PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma. (PubMed, J Exp Clin Cancer Res)
    Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib...Furthermore, cancer-associated fibroblasts (CAFs) were identified as the major source of IGF1 in CCA microenvironment, essential for IGF1R-driven tumor progression.In summary, the PTPN9-IGF1R axis plays a pivotal role in modulating mTKI sensitivity and tumor progression in CCA. This axis serves as a promising biomarker for identifying potential mTKI beneficiaries and represents a potential therapeutic target to enhance mTKI efficacy and overcome resistance.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Sulanda (surufatinib)
    25d
    A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy. (PubMed, Front Cell Dev Biol)
    From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    everolimus • Sulanda (surufatinib) • octreotide acetate
    1m
    Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial. (PubMed, Cell Oncol (Dordr))
    Surufatinib plus paclitaxel showed promising efficacy and manageable safety as second-line treatment for advanced gastric cancer, especially in patients who had failed prior immunotherapy.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Sulanda (surufatinib)
    3ms
    Open-label Study of Surufatinib in Japanese Patients (clinicaltrials.gov)
    P1/2, N=36, Completed, Hutchmed | Active, not recruiting --> Completed
    Trial completion
    |
    Sulanda (surufatinib)
    3ms
    Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • Sulanda (surufatinib)
    3ms
    Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=21, Completed, Hutchison Medipharma Limited | Recruiting --> Completed | N=60 --> 21
    Trial completion • Enrollment change
    |
    Sulanda (surufatinib)
    4ms
    An exploratory clinical study of surufatinib combined with standard chemotherapy as first-line treatment in advanced osteosarcoma and soft tissue sarcoma (ChiCTR2500105216)
    P4, N=30, Not yet recruiting, Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University
    New P4 trial
    |
    Sulanda (surufatinib)
    4ms
    A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=65, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    4ms
    NAT10 Increases Lysosomal Acidification to Promote Esophageal Cancer Metastasis via ac4C Acetylation of ATP6V0E1 mRNA. (PubMed, Adv Sci (Weinh))
    Furthermore, G-749 is screened and identified as a novel NAT10 inhibitor capable of effectively impeding lysosomal acidification and tumor metastasis by disrupting the NAT10-Ubiquitin-specific Peptidase 39 (USP39) interaction. Overall, the results unveil a novel role of ac4C modifications in regulating lysosomal acidification and propose a potential strategy by targeting NAT10 to inhibit esophageal cancer metastasis.
    Journal
    |
    CDH1 (Cadherin 1)
    |
    denfivontinib (SKI-G-801)
    4ms
    Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    4ms
    Open-Label Surufatinib in European Patients With NET (clinicaltrials.gov)
    P2, N=78, Terminated, Hutchmed | Completed --> Terminated; Sponsor decision
    Trial termination
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Sulanda (surufatinib)